간질 모니터링 기기 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the epilepsy monitoring devices market size in 2026 is estimated at USD 621.62 million, growing from 2025 value of USD 591.34 million with 2031 projections showing USD 797.85 million, growing at 5.12% CAGR over 2026-2031.

This report is Segmented by Product (Conventional Devices and Wearable Devices), Technology (Vagus Nerve Stimulation, Deep Brain Stimulation, and More), Detection Modality (Electroencephalogram, Intracranial EEG, and More), End User (Hospitals & Ambulatory Surgery Centers, Neurology Centers and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Epilepsy Monitoring Devices Market Trends and Insights

Growing Adoption of Wearable Seizure-Detection Devices

Consumer eagerness for unobtrusive health technology has accelerated uptake of wrist-, head- and ear-worn monitors that capture EEG, electromyography (EMG) and motion signals in real time. Validation studies reported 97.7% sensitivity with merely 0.4 false positives per day. This clinical-grade accuracy-delivered without hospital admission-has motivated physicians to recommend wearables to the estimated 30% of patients whose seizures persist despite medication. Data from thousands of devices feed federated-learning models that refine population-level seizure forecasts, raising overall predictive reliability while guarding patient privacy.

Technological Advances in EEG & AI-Enabled Analytics

Deep-learning architectures including temporal convolutional networks and self-attention layers reach automated seizure-detection accuracy of 97.37%, surpassing classical signal processing benchmarks. Cloud platforms further upgrade performance through continuous model retraining using de-identified data. As a result, EEG systems transition from passive monitors to intelligent therapeutic hubs that trigger neurostimulation or medication reminders pre-ictally, thus justifying higher device prices and bolstering the epilepsy monitoring devices market.

High Cost of Equipment

Price gaps exceeding 300% between entry-level EEG units and AI-enabled platforms deter purchases in cost-sensitive health systems. Administrators in lower-income regions often select portable, channel-limited devices that sacrifice predictive analytics to meet budget ceilings. This tiered adoption stalls penetration of high-margin systems, pressing suppliers to launch stripped-down variants aimed at volume markets while preserving premium lines for developed economies.

Other drivers and restraints analyzed in the detailed report include:

1. Integration of Seizure-Forecasting Algorithms into Tele-Neurology Platforms
2. Expansion of US RPM CPT Codes to Epilepsy Monitoring
3. Stringent Data-Privacy Rules Hindering Cloud-Based EEG Analytics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Conventional systems generated 51.72% of revenue in 2025, reflecting their entrenched role in hospital diagnostics. The epilepsy monitoring devices market size for conventional equipment is projected to expand modestly alongside replacement cycles, yet competitive differentiation narrows as software features become standard. Wearables, in contrast, post a 9.61% CAGR by 2031 on the back of patient-centric design that eliminates inpatient stays. Ear-EEG headsets now hit clinical-grade performance, achieving seizure detection accuracy comparable to multi-channel scalp arrays. The epilepsy monitoring devices market benefits from hybrid offerings that pair hospital-grade baseline studies with long-duration wearables, extending monitoring coverage without inflating clinician workload.

In ambulatory care, reimbursement alignment with remote-patient-monitoring codes accelerates wearable uptake across United States practices. Suppliers integrate cloud dashboards that flag anomalies, freeing neurologists to focus on high-risk cases. Meanwhile, conventional system makers retrofit hardware with AI modules to preserve market relevance. These parallel strategies keep both product classes integral to comprehensive care pathways, although growth clearly tilts toward wearables.

Vagus nerve stimulation led revenue at 36.05% in 2025, underpinned by a two-decade safety record and broad clinical indications. The epilepsy monitoring devices market size for VNS is expected to rise steadily, supported by pediatric approvals. Responsive neurostimulation excels with an 8.28% CAGR, driven by closed-loop algorithms that deliver stimulation precisely when abnormal activity is sensed. Hospitals view RNS as a high-margin solution for medication-refractory patients, while payers recognize its cost-offset potential through seizure reduction.

Deep brain stimulation and accelerometry-only devices cover niche indications yet remain clinically essential. The competitive axis shifts from hardware prowess to software sophistication, with algorithm accuracy dictating therapeutic outcomes. Companies that couple proprietary datasets with machine-learning expertise erect defensible moats, reshaping long-term leadership in the epilepsy monitoring devices market.

Complete Report Scope:

• By Product
  • Conventional Devices
  • Wearable Devices
• By Technology
  • Vagus Nerve Stimulation (VNS)
  • Deep Brain Stimulation (DBS)
  • Accelerometry
  • Responsive Neuro-stimulation (RNS)
• By Detection Modality
  • Electroencephalogram (EEG)
  • Intracranial EEG (iEEG)
  • Surface Electromyography (sEMG)
  • Video Detection Systems
• By End User
  • Hospitals & Ambulatory Surgery Centers
  • Neurology Centers
  • Diagnostic Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retains primacy with 39.31% of global revenue in 2025, anchored by Medicare-backed reimbursement of long-term monitoring and rapid adoption of FDA-cleared implants such as Epiminder's Minder device. Hospital systems capitalize on RPM billing codes that align precisely with EEG data review intervals, producing immediate financial justification for capital purchases. Canada and Mexico contribute incremental gains through tele-health expansion and cross-border technology partnerships.

Asia Pacific records the highest CAGR at 7.62% through 2031. China accelerates approvals of both drugs and devices, exemplified by Fycompa's 2024 clearance that broadened clinical interest in comprehensive management. Japan and South Korea showcase early adoption of RNS and wearable EEG, leveraging robust insurance coverage and high digital-health literacy. India's neurologist shortage continues to hold back volume growth, yet national telemedicine networks begin to offset access barriers, hinting at accelerating uptake post-infrastructure maturation.

Europe shows moderate expansion, tempered by GDPR compliance costs that force on-premise analytics deployments. Germany and the United Kingdom lead research trials that validate AI algorithms, aiding vendor market entry. Southern European states rely on EU structural funds to modernize epilepsy centers, fostering gradual but uneven growth.

Across the Middle East and Africa, initiatives to localize medical device assembly and targeted training programs lay groundwork for future demand, though present volumes remain small relative to population need.

1. Medpage
2. Boston Scientific
3. Cadwell Industries
4. Compumedics
5. Emfit Corp.
6. Empatica
7. GE Healthcare
8. Koninklijke Philips
9. Masimo Corp.
10. Neurosoft Ltd
11. Neurowave Systems
12. Nihon Kohden Corp.
13. Nonin Medical
14. Medtronic
15. LivaNova plc
16. Natus Medical
17. NeuroPace
18. Seer Medical
19. SeizAlarm LLC
20. BrainScope Co. Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence Of Epilepsy
  • 4.2.2 Rising Awareness Of Neuro-Degenerative Disorders
  • 4.2.3 Growing Adoption Of Wearable Seizure-Detection Devices
  • 4.2.4 Technological Advances In EEG & AI-Enabled Analytics
  • 4.2.5 Integration Of Seizure-Forecasting Algorithms Into Tele-Neurology Platforms
  • 4.2.6 Expansion Of US RPM CPT Codes To Epilepsy Monitoring
• 4.3 Market Restraints
  • 4.3.1 High Cost Of Equipment
  • 4.3.2 Unfavourable Reimbursement Policies In Several Countries
  • 4.3.3 Shortage Of Trained Neurophysiologists In Emerging Markets
  • 4.3.4 Stringent Data-Privacy Rules Hindering Cloud-Based EEG Analytics
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Product
  • 5.1.1 Conventional Devices
  • 5.1.2 Wearable Devices
• 5.2 By Technology
  • 5.2.1 Vagus Nerve Stimulation (VNS)
  • 5.2.2 Deep Brain Stimulation (DBS)
  • 5.2.3 Accelerometry
  • 5.2.4 Responsive Neuro-stimulation (RNS)
• 5.3 By Detection Modality
  • 5.3.1 Electroencephalogram (EEG)
  • 5.3.2 Intracranial EEG (iEEG)
  • 5.3.3 Surface Electromyography (sEMG)
  • 5.3.4 Video Detection Systems
• 5.4 By End User
  • 5.4.1 Hospitals & Ambulatory Surgery Centers
  • 5.4.2 Neurology Centers
  • 5.4.3 Diagnostic Centers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Medpage Ltd
  • 6.3.2 Boston Scientific Corp.
  • 6.3.3 Cadwell Industries
  • 6.3.4 Compumedics Ltd
  • 6.3.5 Emfit Corp.
  • 6.3.6 Empatica Inc.
  • 6.3.7 GE HealthCare
  • 6.3.8 Koninklijke Philips N.V.
  • 6.3.9 Masimo Corp.
  • 6.3.10 Neurosoft Ltd
  • 6.3.11 Neurowave Systems
  • 6.3.12 Nihon Kohden Corp.
  • 6.3.13 Nonin Medical
  • 6.3.14 Medtronic plc
  • 6.3.15 LivaNova plc
  • 6.3.16 Natus Medical Inc.
  • 6.3.17 NeuroPace Inc.
  • 6.3.18 Seer Medical
  • 6.3.19 SeizAlarm LLC
  • 6.3.20 BrainScope Co. Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment